ArticleGut2018
Epidermal growth factor receptor inhibition downregulates
Abstract read
In one paragraph
Article in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 79 citations in OpenAlex.
- Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.Cancer prevention research (Philadelphia, Pa.) · 2026Trial
- Conventional and Novel Approaches to Establishing Mouse Models of Gastric Cancer in the Past, Present, and Potential Post-H. Pylori Infection Era.Biological procedures online · 2026Review
- Integrated transcriptomics and molecular docking identify hub genes and statin regulators inFrontiers in cellular and infection microbiology · 2026Article
- Research advancements and evaluation of multifactor-induced murine models for gastric cancer.Animal models and experimental medicine · 2025Review
- Ménétrier Disease: Rare Manifestations and Mechanistic Insights From 2 Adult Cases.The American journal of case reports · 2025Article
- Spermine oxidase promotes Helicobacter pylori-mediated gastric carcinogenesis through acrolein production.Oncogene · 2025Article
- Alterations in polyamine metabolism induced by the pathogen Helicobacter pylori: Implications for gastric inflammation and carcinogenesis.Methods in enzymology · 2025Article
- The intersection ofFrontiers in cellular and infection microbiology · 2025Review
- Comparison of gastric inflammation and metaplasia induced byMicrobiology spectrum · 2024Article
- Article
- PDE5 inhibitors and gastric mucosa: implications for the management of peptic ulcer disease.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Review
- The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- High-throughput computational screening andOncology research · 2023Article
- Ornithine Decarboxylase in Gastric Epithelial Cells Promotes the Immunopathogenesis ofJournal of immunology (Baltimore, Md. : 1950) · 2022Article
- The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs.International journal of molecular sciences · 2022Review
- Cystathionine γ-lyase exacerbates Helicobacter pylori immunopathogenesis by promoting macrophage metabolic remodeling and activation.JCI insight · 2022Article
- Update on the role of C1GALT1 in cancer.Oncology letters · 2022Review
- Investigating the Active Substance and Mechanism of San-Jiu-Wei-Tai Granules via UPLC-QE-Orbitrap-MS and Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Assessment of the Potential ofFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Johanna C SierraDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mohammad AsimDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Thomas G VerriereDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
M Blanca PiazueloDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Giovanni SuarezDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Judith Romero-GalloDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alberto G DelgadoDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Lydia E WroblewskiDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Daniel P BarryDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-3972-3914
Richard M PeekDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alain P GobertDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Keith T WilsonDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Vanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MRole of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2009 to 2026
$27.5MProject 3 - Molecular Signatures of Gastric Carcinogenesis in the Host Response to H. pyloriP01CA028842 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 1985 to 2019
$15.8MH.Pylori Relationship to Digestive Diseases and CancerR01CA077955 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2003 to 2026
$9.7MHelicobacter Pylori and Gastrointestinal BiologyR01DK058587 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEK, RICHARD M. · 2001 to 2024
$7.8MImmunomodulatory effects of arginine supplementation in colitis and colon cancerR01AT004821 · NCCIH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 2008 to 2017
$4.0MHPYLORI INDUCED DNA DAMAGE AND IMMUNE DYSREGULATIONR01DK053620 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 1997 to 2014
$3.4MTargeted chemoprevention of gastric carcinogenesis in high risk populationsR01CA190612 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MORGAN, DOUGLAS, WILSON, KEITH T. · 2014 to 2018
$3.0MArginine Availability and Metabolism in the Immune Evasion of H. pyloriI01BX001453 · VA · VETERANS HEALTH ADMINISTRATION · PI WILSON, KEITH T. · 2012 to 2019
–BLRD VA I01 BX001453NCCIH NIH HHS R01 AT004821NCI NIH HHS P01 CA028842NCI NIH HHS P01 CA116087NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA077955NCI NIH HHS R01 CA190612NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK053620NIDDK NIH HHS R01 DK058587
Abstract
objectiveGastric cancer is the third leading cause of cancer death worldwide and infection by
designWe evaluated gefitinib, a specific EGFR inhibitor, in chemoprevention of
resultsIn C57BL/6 mice, gefitinib decreased
conclusionsThese findings suggest that epithelial EGFR inhibition represents a potential strategy to prevent development of gastric carcinoma in
Indexed as
AnimalsAntineoplastic AgentsCell Culture TechniquesEpithelial CellsErbB ReceptorsGastritisGefitinibGerbillinaeHelicobacter InfectionsHelicobacter pyloriMiceMice, Inbred C57BLQuinazolinesStomach NeoplasmsAntineoplastic AgentsErbB ReceptorsGefitinibQuinazolinesCHEMOKINESCHEMOPREVENTIONEPIDERMAL GROWTH FACTORGASTRIC CANCERHELICOBACTER PYLORI
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.